Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Soligenix Inc (SNGX)

Soligenix Inc (SNGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Soligenix's RiVax(R) Program Back in Focus After Deadly Ricin Toxin Intercepted Before Reaching White House

New York, New York--(Newsfile Corp. - September 21, 2020) - Soligenix's (NASDAQ: SNGX) RiVax® program is in focus after a failed attempt to send ricin-laced letters to the White House last week raised...

SNGX : 1.7300 (-0.57%)
Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens

, /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there...

SNGX : 1.7300 (-0.57%)
Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine

, /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there...

SNGX : 1.7300 (-0.57%)
Soligenix Invited to Present at Upcoming Virtual Investor Conferences

, /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there...

SNGXD : 4.1500 (-5.68%)
SNGX : 1.7300 (-0.57%)
Soligenix Announces Investor Webcast Event: Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine

, /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there...

SNGX : 1.7300 (-0.57%)
Soligenix to Present at the LD Micro Conference

, /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there...

SNGXD : 4.1500 (-5.68%)
SNGX : 1.7300 (-0.57%)
Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis

, /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there...

SNGXD : 4.1500 (-5.68%)
SNGX : 1.7300 (-0.57%)
Soligenix to Join Russell Microcap® Index

, /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there...

SNGXD : 4.1500 (-5.68%)
SNGX : 1.7300 (-0.57%)
Soligenix to Present at the MedInvest Infectious Disease and Immunology Investor Conference

, /PRNewswire/ --Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there...

SNGX : 1.7300 (-0.57%)
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results

, /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there...

SNGX : 1.7300 (-0.57%)
BSX : 37.42 (+0.81%)
Soligenix Announces Publication of Correlates of Immune Protection for the RiVax® Ricin Toxin Vaccine

, /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there...

SNGX : 1.7300 (-0.57%)
Soligenix Receives $840,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

, /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there...

SNGXD : 4.1500 (-5.68%)
SNGX : 1.7300 (-0.57%)
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma

, /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there...

SNGX : 1.7300 (-0.57%)
Soligenix Announces Exclusive Licensing Agreement for Novel Vaccine Adjuvant from BTG Specialty Pharmaceuticals

Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced...

SNGXD : 4.1500 (-5.68%)
SNGX : 1.7300 (-0.57%)
BSX : 37.42 (+0.81%)
Soligenix Receives European Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical...

SNGXD : 4.1500 (-5.68%)
SNGX : 1.7300 (-0.57%)
Soligenix Announces Recent Accomplishments And Year-End 2019 Financial Results

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical...

SNGXD : 4.1500 (-5.68%)
SNGX : 1.7300 (-0.57%)
Soligenix Inc. Heat-Stabilization Platform Evaluating Use With COVID-19 Vaccine; Zacks Small-Cap Research Increases Valuation To $12.00 Per Share

New York, New York--(Newsfile Corp. - March 24, 2020) - Soligenix Inc. (NasdaqGS: SNGX), through its Public Health Solutions business segment, on Monday that the company is expanding its ongoing collaboration...

SNGXD : 4.1500 (-5.68%)
SNGX : 1.7300 (-0.57%)
Soligenix and University of HawaiÊ"i at Manoa Initiate Work on Novel Coronavirus Vaccine for COVID-19

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical...

SNGXD : 4.1500 (-5.68%)
SNGX : 1.7300 (-0.57%)
Soligenix, Inc. Impresses With Statistically Significant Topline Phase 3 Data From SGX301 FLASH Trial; Targets $250 Million CTCL Patient Market

New York, New York--(Newsfile Corp. - March 20, 2020) - Soligenix, on Thursday, announced positive topline data for its lead CTCL drug candidate, SGX301. The published data demonstrated statistically significant...

SNGXD : 4.1500 (-5.68%)
SNGX : 1.7300 (-0.57%)
Soligenix Announces Positive Top-line Results for its Pivotal Phase 3 FLASH Trial Evaluating SGX301 in Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical...

SNGXD : 4.1500 (-5.68%)
SNGX : 1.7300 (-0.57%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar